



UNITED STATES PATENT AND TRADEMARK OFFICE

UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND
DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE

JULY 25, 2018

PTAS

ANDREW PRESLEY
KILPATRICK TOWNSEND AND STOCKTON LLP
1100 PEACHTREE STREET, SUITE 2800
ATLANTA, GA 30309

505018558

UNITED STATES PATENT AND TRADEMARK OFFICE NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT RECORDATION BRANCH OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE ASSIGNMENT RECORDATION BRANCH AT 571-272-3350. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, MAIL STOP: ASSIGNMENT RECORDATION BRANCH, P.O. BOX 1450, ALEXANDRIA, VA 22313.

RECORDATION DATE: 07/24/2018

REEL/FRAME: 046448/0120
NUMBER OF PAGES: 8

BRIEF: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

DOCKET NUMBER: 104094-000200US-1086575

ASSIGNOR:

MAAG, HANS

DOC DATE: 07/13/2018

ASSIGNOR:

FERNANDES, MIGUEL XAVIER

DOC DATE: 07/11/2018

ASSIGNOR:

ZAMBONI, ROBERT

DOC DATE: 07/23/2018

ASSIGNOR:

AKBARIROMANI, ELHAM

DOC DATE: 07/13/2018

ASSIGNOR:

BEAULIEU, MARC-ANDRE

DOC DATE: 07/13/2018

ASSIGNOR:

LEBLANC, YVES

DOC DATE: 07/13/2018

ASSIGNOR:

THAKUR, PALLAVI

DOC DATE: 07/13/2018

ASSIGNEE:

ORFAN BIOTECH INC.
421 KIPLING STREET
PALO ALTO, CALIFORNIA 94301

APPLICATION NUMBER: 62694918

FILING DATE: 07/06/2018

PATENT NUMBER:

ISSUE DATE:

TITLE: TRIAZOLE GLYCOLATE OXIDASE INHIBITORS

ASSIGNMENT RECORDATION BRANCH
PUBLIC RECORDS DIVISION

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5065306

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
HANS MAAG	07/13/2018
MIGUEL XAVIER FERNANDES	07/11/2018
ROBERT ZAMBONI	07/23/2018
ELHAM AKBARIROMANI	07/13/2018
MARC-ANDRE BEAULIEU	07/13/2018
YVES LEBLANC	07/13/2018
PALLAVI THAKUR	07/13/2018
RECEIVING PARTY DATA	
Name:	ORFAN BIOTECH INC.
Street Address:	421 KIPLING STREET
City:	PALO ALTO
State/Country:	CALIFORNIA
Postal Code:	94301
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	62694918
CORRESPONDENCE DATA	
Fax Number:	(650)326-2422
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	650-326-2400
Email:	lweaver@kilpatricktownsend.com
Correspondent Name:	ANDREW PRESLEY
Address Line 1:	KILPATRICK TOWNSEND AND STOCKTON LLP
Address Line 2:	1100 PEACHTREE STREET, SUITE 2800
Address Line 4:	ATLANTA, GEORGIA 30309
ATTORNEY DOCKET NUMBER:	104094-000200US-1086575
NAME OF SUBMITTER:	LISA WEAVER
SIGNATURE:	/Lisa Weaver/
DATE SIGNED:	07/24/2018

ASSIGNMENT
(Patent Application)

We, the undersigned, have invented certain inventions and improvements disclosed in a utility (provisional or non-provisional) or design patent application entitled

“TRIAZOLE GLYCOLATE OXIDASE INHIBITORS,”

filed with the U.S. Patent & Trademark Office on July 6, 2018

and assigned serial no. 62/694,918.

For good and valuable consideration, the receipt and sufficiency of which we acknowledge, we:

1. Agree to assign, transfer, convey, and sell, hereby assign, transfer, convey, and sell and have assigned, transferred, conveyed, and sold to Orfan Biotech Inc., having a principal place of business at 421 Kipling Street, Palo Alto, CA 94301 (“Assignee”), the entire right, title, and interest in and to:
 - (a) all intellectual property (including, without limitation, any innovation, information, invention, discovery, product, process, work or design) disclosed, embodied, shown, or claimed in the above-referenced patent application, implicitly or explicitly;
 - (b) the above-referenced patent application, and all applications based in whole or in part upon the above-referenced patent application, including, without limitation, all applications that are a provisional, non-provisional, design, divisional, continuation, continuation-in-part, registration, utility model, industrial design, reissue, renewal, substitute, extension, reexamination, post-grant review, inter partes review, supplemental examination or non-U.S. patent application or application for other rights based in whole or in part on the above-referenced patent application;
 - (c) the right to claim priority to the above-referenced patent application, and any and all applications referenced in subsection (b); and
 - (d) all patents (including, without limitation, all U.S. and non-U.S. patents, registrations, utility models, industrial designs, design patents, counterparts, continuations, continuations-in-part, divisionals, reissues, renewals, substitutes, extensions, reexaminations, post-grant reviews, inter partes reviews and supplemental examinations) that are granted or issued upon, or that claim priority to, any and all applications described in (b) of this paragraph or that disclose or claim intellectual property described in (a) of this paragraph, in whole or in part; and
 - (e) all claims for damages by reason of past infringement of any rights under the applications or patents described in (a), (b) or (c) of this paragraph (including provisional rights to reasonable royalties pursuant to 35 U.S.C. §154(d)) and the right to sue for and collect such damages and royalties for Assignee’s own use.
2. Authorize and request the U.S. Patent and Trademark Office or any other U.S. or non-U.S. agency to issue to the Assignee any and all patent(s), or other rights or documents, resulting from the intellectual property, patent application(s) and patents described in paragraph 1 of this Assignment.
3. Agree to sign all papers and documents, including without limitation, applications, declarations, oaths and petitions, and, at the Assignee’s expense, perform any other acts that are necessary in connection with prosecution of patent application(s) or intellectual property described in paragraph 1 of this

ASSIGNMENT

U.S. Serial No. 62/694,918


Attorney Docket No. 104094-000200US-1086575

Page 2 of 2

Assignment and the enforcement of patent(s) or other rights resulting from such patent application(s) or intellectual property.

4. Agree that the terms, covenants, and conditions of this Assignment shall inure to the benefit of the Assignee, its successors, assigns and other legal representative, and shall be binding upon us, as well as our heirs, legal representatives, and assigns.
5. Promise and affirm that we have not entered, and will not enter, into any assignment, contract, or understanding that conflicts with this Assignment.

Signed on the dates indicated beside our signatures.

Signature:  Date: July 13, 2018
Hans Maag

Signature: _____ Date: _____
Miguel Xavier Fernandes

Signature: _____ Date: _____
Robert Zamboni

Signature: _____ Date: _____
Elham Akbariromani

Signature: _____ Date: _____
Marc-Andre Beaulieu

Signature: _____ Date: _____
Yves Leblanc

Signature: _____ Date: _____
Pallavi Thakur

ASSIGNMENT

U.S. Serial No. 62/694,918

Attorney Docket No. 104094-000200US-1086575

Page 2 of 2

Assignment and the enforcement of patent(s) or other rights resulting from such patent application(s) or intellectual property.

4. Agree that the terms, covenants, and conditions of this Assignment shall inure to the benefit of the Assignee, its successors, assigns and other legal representative, and shall be binding upon us, as well as our heirs, legal representatives, and assigns.
5. Promise and affirm that we have not entered, and will not enter, into any assignment, contract, or understanding that conflicts with this Assignment.

Signed on the dates indicated beside our signatures.

Signature: _____

Hans Maag

Date: _____

Signature: _____

Miguel Xavier Fernandes

Date: July 11th 2018

Signature: _____

Robert Zamboni

Date: _____

Signature: _____

Elham Akbariromani

Date: _____

Signature: _____

Marc-Andre Beaulieu

Date: _____

Signature: _____

Yves Leblanc

Date: _____

Signature: _____

Pallavi Thakur

Date: _____

ASSIGNMENT

U.S. Serial No. 62/694,918

Attorney Docket No. 104094-000200US-1086575

Page 2 of 2

Assignment and the enforcement of patent(s) or other rights resulting from such patent application(s) or intellectual property.

4. Agree that the terms, covenants, and conditions of this Assignment shall inure to the benefit of the Assignee, its successors, assigns and other legal representative, and shall be binding upon us, as well as our heirs, legal representatives, and assigns.
5. Promise and affirm that we have not entered, and will not enter, into any assignment, contract, or understanding that conflicts with this Assignment.

Signed on the dates indicated beside our signatures.

Signature: _____
Hans Maag

Date: _____

Signature: _____
Miguel Xavier Fernandes

Date: _____

Signature: Robert Zamboni
Robert Zamboni

Date: July 23, 2018

Signature: _____
Elham Akbariromani

Date: _____

Signature: _____
Marc-Andre Beaulieu

Date: _____

Signature: _____
Yves Leblanc

Date: _____

Signature: _____
Pallavi Thakur

Date: _____

ASSIGNMENT

U.S. Serial No. 62/694,918

Attorney Docket No. 104094-000200US-1086575

Page 2 of 2

Assignment and the enforcement of patent(s) or other rights resulting from such patent application(s) or intellectual property.

4. Agree that the terms, covenants, and conditions of this Assignment shall inure to the benefit of the Assignee, its successors, assigns and other legal representative, and shall be binding upon us, as well as our heirs, legal representatives, and assigns.
5. Promise and affirm that we have not entered, and will not enter, into any assignment, contract, or understanding that conflicts with this Assignment.

Signed on the dates indicated beside our signatures.

Signature: _____
Hans Maag

Date: _____

Signature: _____
Miguel Xavier Fernandes

Date: _____

Signature: _____
Robert Zamboni

Date: _____

Signature: _____
Elham Akbariromani

Date: July 13 - 2018

Signature: _____
Marc-Andre Beaulieu

Date: _____

Signature: _____
Yves Leblanc

Date: July 13th / 2018

Signature: _____
Pallavi Thakur

Date: 13th July. 2018.

ASSIGNMENT

U.S. Serial No. 62/694,918

Attorney Docket No. 104094-000200US-1086575

Page 2 of 2

Assignment and the enforcement of patent(s) or other rights resulting from such patent application(s) or intellectual property.

4. Agree that the terms, covenants, and conditions of this Assignment shall inure to the benefit of the Assignee, its successors, assigns and other legal representative, and shall be binding upon us, as well as our heirs, legal representatives, and assigns.
5. Promise and affirm that we have not entered, and will not enter, into any assignment, contract, or understanding that conflicts with this Assignment.

Signed on the dates indicated beside our signatures.

Signature: _____
Hans Maag

Date: _____

Signature: _____
Miguel Xavier Fernandes


Date: _____

Signature: _____
Robert Zamboni

Date: _____

Signature: _____
Elham Akbariromani

Date: _____

Signature: 
Marc-Andre Beaulieu

Date: July 13th, 2018

Signature: _____
Yves Leblanc

Date: _____

Signature: _____
Pallavi Thakur

Date: _____



UNITED STATES PATENT AND TRADEMARK OFFICE

UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND
DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE

MAY 23, 2019

PTAS

SYLVIA ARNOLD
KILPATRICK TOWNSEND & STOCKTON LLP
1100 PEACHTREE STREET, SUITE 2800
ATLANTA, GA 30309

505488696

UNITED STATES PATENT AND TRADEMARK OFFICE NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT RECORDATION BRANCH OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE ASSIGNMENT RECORDATION BRANCH AT 571-272-3350. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, MAIL STOP: ASSIGNMENT RECORDATION BRANCH, P.O. BOX 1450, ALEXANDRIA, VA 22313.

RECORDATION DATE: 05/22/2019

REEL/FRAME: 049254/0601
NUMBER OF PAGES: 6

BRIEF: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

DOCKET NUMBER: 104094-000210US-1119040

ASSIGNOR:

MAAG, HANS

DOC DATE: 04/02/2019

ASSIGNOR:

FERNANDES, MIGUEL XAVIER

DOC DATE: 04/02/2019

ASSIGNOR:

ZAMBONI, ROBERT

DOC DATE: 04/08/2019

ASSIGNOR:

AKBARIROMANI, ELHAM

DOC DATE: 04/02/2019

ASSIGNOR:

BEAULIEU, MARC-ANDRE

DOC DATE: 04/02/2019

ASSIGNOR:

LEBLANC, YVES

DOC DATE: 04/02/2019

ASSIGNOR:

THAKUR, PALLAVI

DOC DATE: 04/02/2019

ASSIGNEE:

ORFAN BIOTECH INC.
421 KIPLING STREET
PALO ALTO, CALIFORNIA 94301

APPLICATION NUMBER: 62827573

FILING DATE: 04/01/2019

PATENT NUMBER:

ISSUE DATE:

TITLE: TRIAZOLE GLYCOLATE OXIDASE INHIBITORS

ASSIGNMENT RECORDATION BRANCH
PUBLIC RECORDS DIVISION

ASSIGNMENT
(Patent Application)

We, the undersigned, have invented certain inventions and improvements disclosed in a utility (provisional or non-provisional) or design patent application entitled

“TRIAZOLE GLYCOLATE OXIDASE INHIBITORS,”

filed with the U.S. Patent & Trademark Office on April 1, 2019

and assigned serial no. 62/827,573.

For good and valuable consideration, the receipt and sufficiency of which we acknowledge, we:

1. Agree to assign, transfer, convey, and sell, hereby assign, transfer, convey, and sell and have assigned, transferred, conveyed, and sold to Orfan Biotech Inc., having a principal place of business at 421 Kipling Street, Palo Alto, CA 94301 (“Assignee”), the entire right, title, and interest in and to:
 - (a) all intellectual property (including, without limitation, any innovation, information, invention, discovery, product, process, work or design) disclosed, embodied, shown, or claimed in the above-referenced patent application, implicitly or explicitly;
 - (b) the above-referenced patent application, and all applications based in whole or in part upon the above-referenced patent application, including, without limitation, all applications that are a provisional, non-provisional, design, divisional, continuation, continuation-in-part, registration, utility model, industrial design, reissue, renewal, substitute, extension, reexamination, post-grant review, inter partes review, supplemental examination or non-U.S. patent application or application for other rights based in whole or in part on the above-referenced patent application;
 - (c) the right to claim priority to the above-referenced patent application, and any and all applications referenced in subsection (b); and
 - (d) all patents (including, without limitation, all U.S. and non-U.S. patents, registrations, utility models, industrial designs, design patents, counterparts, continuations, continuations-in-part, divisionals, reissues, renewals, substitutes, extensions, reexaminations, post-grant reviews, inter partes reviews and supplemental examinations) that are granted or issued upon, or that claim priority to, any and all applications described in (b) of this paragraph or that disclose or claim intellectual property described in (a) of this paragraph, in whole or in part; and
 - (e) all claims for damages by reason of past infringement of any rights under the applications or patents described in (a), (b) or (c) of this paragraph (including provisional rights to reasonable royalties pursuant to 35 U.S.C. §154(d)) and the right to sue for and collect such damages and royalties for Assignee’s own use.
2. Authorize and request the U.S. Patent and Trademark Office or any other U.S. or non-U.S. agency to issue to the Assignee any and all patent(s), or other rights or documents, resulting from the intellectual property, patent application(s) and patents described in paragraph 1 of this Assignment.
3. Agree to sign all papers and documents, including without limitation, applications, declarations, oaths and petitions, and, at the Assignee’s expense, perform any other acts that are necessary in connection with prosecution of patent application(s) or intellectual property described in paragraph 1 of this

ASSIGNMENT

U.S. Serial No. 62/827,537


Attorney Docket No. 104094-000210US-1119040


Page 2 of 2

Assignment and the enforcement of patent(s) or other rights resulting from such patent application(s) or intellectual property.

4. Agree that the terms, covenants, and conditions of this Assignment shall inure to the benefit of the Assignee, its successors, assigns and other legal representative, and shall be binding upon us, as well as our heirs, legal representatives, and assigns.
5. Promise and affirm that we have not entered, and will not enter, into any assignment, contract, or understanding that conflicts with this Assignment.

Signed on the dates indicated beside our signatures.

Signature:  Date: 4/2/2019
Hans Maag

Signature:  Date: 04/02/2019
Miguel Xavier Fernandes

Signature: _____ Date: _____
Robert Zamboni

Signature: _____ Date: _____
Elham Akbariromani

Signature: _____ Date: _____
Marc-Andre Beaulieu

Signature: _____ Date: _____
Yves Leblanc

Signature: _____ Date: _____
Pallavi Thakur

ASSIGNMENT

U.S. Serial No. 62/827,537

Attorney Docket No. 104094-000210US-1119040

Page 2 of 2

Assignment and the enforcement of patent(s) or other rights resulting from such patent application(s) or intellectual property.

4. Agree that the terms, covenants, and conditions of this Assignment shall inure to the benefit of the Assignee, its successors, assigns and other legal representative, and shall be binding upon us, as well as our heirs, legal representatives, and assigns.
5. Promise and affirm that we have not entered, and will not enter, into any assignment, contract, or understanding that conflicts with this Assignment.

Signed on the dates indicated beside our signatures.

Signature: _____
Hans Maag

Date: _____

Signature: _____
Miguel Xavier Fernandes

Date: _____

Signature: _____
Robert Zamboni

Date: _____

Signature: _____
Elham Akbariromani

Date: 02-04-2019

Signature: _____
Marc-Andre Beaulieu

Date: 02-04-2019

Signature: _____
Yves Leblanc

Date: APRIL 2nd / 2019

Signature: _____
Pallavi Thakur

Date: 2nd. April. 2019.

ASSIGNMENT

U.S. Serial No. 62/827,537

Attorney Docket No. 104094-000210US-1119040

Page 2 of 2

Assignment and the enforcement of patent(s) or other rights resulting from such patent application(s) or intellectual property.

4. Agree that the terms, covenants, and conditions of this Assignment shall inure to the benefit of the Assignee, its successors, assigns and other legal representative, and shall be binding upon us, as well as our heirs, legal representatives, and assigns.
5. Promise and affirm that we have not entered, and will not enter, into any assignment, contract, or understanding that conflicts with this Assignment.

Signed on the dates indicated beside our signatures.

Signature: _____

Hans Maag

Date: _____

Signature: _____

Miguel Xavier Fernandes

Date: _____

Signature: Robert Zamboni

Robert Zamboni

Date: April 8, 2019

Signature: _____

Elham Akbariromani

Date: _____

Signature: _____

Marc-Andre Beaulieu

Date: _____

Signature: _____

Yves Leblanc

Date: _____

Signature: _____

Pallavi Thakur

Date: _____